Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Submits Januvia/Metformin NDA Aiming To Launch First Fixed-Dose DPP-4 Inhibitor

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis, meanwhile, is positioning its investigational DPP-4 inhibitor Galvus as an add-on to metformin.

You may also be interested in...



Merck Builds On Januvia Momentum With Two Supplementary Claims

Recently announced sNDAs have October action dates and seek indications relating to initial and add-on use with metformin or sulfonylureas.

Merck Builds On Januvia Momentum With Two Supplementary Claims

Recently announced sNDAs have October action dates and seek indications relating to initial and add-on use with metformin or sulfonylureas.

Merck Janumet Study Demonstrates Glucose Reductions In Two Measures

Data on the investigational type 2 diabetes drug is pivotal to Merck’s NDA submission for the sitagliptin/metformin combination.

Related Content

Topics

UsernamePublicRestriction

Register

PS064615

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel